MeiraGTx Holdings plcMGTXEarnings & Financial Report
MeiraGTx Holdings plc is a clinical-stage biotechnology firm specializing in the research, development and commercialization of transformative gene therapies. Its core pipeline targets rare ophthalmic conditions, neurodegenerative disorders, and salivary gland diseases, serving patients across global markets with operations in the U.S. and European Union.
MGTX Q3 FY2025 Key Financial Metrics
Revenue
$410.0K
Gross Profit
N/A
Operating Profit
$-46.1M
Net Profit
$-50.5M
Gross Margin
N/A
Operating Margin
-11232.0%
Net Margin
-12320.2%
YoY Growth
-96.2%
EPS
$-0.62
MeiraGTx Holdings plc Q3 FY2025 Financial Summary
MeiraGTx Holdings plc reported revenue of $410.0K (down 96.2% YoY) for Q3 FY2025, with a net profit of $-50.5M (down 28.4% YoY) (-12320.2% margin).
Key Financial Metrics
| Total Revenue | $410.0K |
|---|---|
| Net Profit | $-50.5M |
| Gross Margin | N/A |
| Operating Margin | -11232.0% |
| Report Period | Q3 FY2025 |
MeiraGTx Holdings plc Annual Revenue by Year
MeiraGTx Holdings plc annual revenue history includes year-by-year totals (for example, 2024 revenue was $33.3M).
MeiraGTx Holdings plc Quarterly Revenue & Net Profit History
MeiraGTx Holdings plc results over the last 8 reported quarters, including revenue, net profit and year-over-year growth.
| Quarter | Revenue | Revenue YoY | Net Profit | Net Margin |
|---|---|---|---|---|
| Q3 FY2025 | $410.0K | -96.2% | $-50.5M | -12320.2% |
| Q2 FY2025 | $3.7M | +1208.9% | $-38.8M | -1051.1% |
| Q4 FY2024 | $21.4M | +948.5% | $-39.4M | -184.2% |
| Q3 FY2024 | $10.9M | +113.8% | $-39.3M | -360.5% |
| Q2 FY2024 | $282.0K | -92.0% | $-48.6M | -17241.1% |
| Q1 FY2024 | $697.0K | -79.1% | $-20.4M | -2932.9% |
| Q4 FY2023 | $2.0M | +138.6% | N/A | N/A |
| Q3 FY2023 | $5.1M | +6.0% | $-44.3M | -868.1% |
Income Statement
| Q3 2023 | Q4 2023 | Q1 2024 | Q2 2024 | Q3 2024 | Q4 2024 | Q2 2025 | Q3 2025 | |
|---|---|---|---|---|---|---|---|---|
| Revenue | $5.1M | $2.0M | $697000 | $282000 | $10.9M | $21.4M | $3.7M | $410000 |
| YoY Growth | 6.0% | 138.6% | -79.1% | -92.0% | 113.8% | 948.5% | 1208.9% | -96.2% |
Balance Sheet
| Q3 2023 | Q4 2023 | Q1 2024 | Q2 2024 | Q3 2024 | Q4 2024 | Q2 2025 | Q3 2025 | |
|---|---|---|---|---|---|---|---|---|
| Assets | $267.2M | $326.7M | $309.2M | $266.7M | $299.5M | $269.8M | $198.7M | $189.5M |
| Liabilities | $175.3M | $188.6M | $187.5M | $186.6M | $203.8M | $201.9M | $195.8M | $230.0M |
| Equity | $91.9M | $138.2M | $121.7M | $80.0M | $95.7M | $67.8M | $3.0M | $-40.6M |
Cash Flow
| Q3 2023 | Q4 2023 | Q1 2024 | Q2 2024 | Q3 2024 | Q4 2024 | Q2 2025 | Q3 2025 | |
|---|---|---|---|---|---|---|---|---|
| Operating CF | $-24.4M | $-105.4M | $-36.7M | $-19.5M | $-25.0M | $-23.3M | $-43.9M | $-12.2M |